The European Bioinformatics Institute has tapped Alex Bateman to head its Protein Sequence Resources unit.
For the last 15 years, Bateman worked at the Wellcome Trust Sanger Institute where he led the development of several databases including Pfam, Rfam, TreeFam, and MEROPS. These resources will move with Bateman over to the EBI, joining its fleet of protein and proteomics resources, which includes the UniProt and InterPro databases.
Bateman also served as the executive editor for the Nucleic Acids Research database issue from 2004 to 2008 and still serves on the journal’s editorial board. He also serves as the executive editor for Bioinformatics, a position he has held since 2004.
He graduated from the University of Newcastle upon Tyne in 1994 with a BSc in biochemistry and then earned his PhD at the Laboratory of Molecular Biology, Cambridge.
Bateman will assume his new position on Nov. 1, taking over from Rolf Apweiler, who was promoted to joint associate director of EBI earlier this year.
Hertfordshire, UK-based Dotmatics has tapped Klaus Rafeiner to lead operations at its newly opened office in Germany.
Under Rafeiner's leadership, the new shop will provide business and technical support for prospective and current customers in continental Europe, Domatics said.
Prior to joining Dotmatics, Klaus worked as a consultant focused on optimizing business processes in research and development in the German, Austrian, and Swiss markets.
Centrillion Biosciences, a provider of genomics and bioinformatics services, has hired Glenn McGall as senior vice president of technology.
Prior to moving to Centrillion, McGall served as vice president of research chemistry at Affymetrix.
GNS Healthcare has hired Hans Winkler to serve as its chief scientific officer.
In his new role, Winkler will promote the development of GNS’ intellectual property, build out product infrastructure, and support the company’s overall scientific strategy for its product offerings in pharmaceutical and biotechnology industry as well as in academia.
Prior to joining GNS, Winkler was the senior director and a global oncology biomarker program leader within Johnson & Johnson’s oncology research and development arm. He also directed the company’s functional genomics and bioinformatics unit.
Before that, Winkler was the director and global program manager for target validation technologies at AstraZeneca. He also researched and taught at Harvard Medical School's Beth Israel Deaconess Hospital focusing on endothelial cell biology and immunobiology.